Natixis Corporate & Investment Banking (Natixis CIB) has completed a €230 million (US$249.8 million) three-year syndicated term loan facility for Fosun Industrial, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group (Fosun Pharma), with the investment bank acting as the sole mandated lead arranger, underwriter and bookrunner.
Based on the strong market response, the syndicated facility was upsized from €200 million to €230 million. Proceeds of the facility will be used for general corporate purposes, including, but not limited to, the funding of general working capital requirements and the refinancing of existing debt.
Fosun Pharma, one of the largest healthcare companies in China, possesses a full industrial value chain, including pharmaceutical manufacturing, healthcare services, medical devices and diagnosis, and pharmaceutical and retail distribution.
“Being part of the strong mix of seven international and Chinese lenders in the syndicated facility highlights the value of our global platform and strong financing expertise,” says Hong Liu, Natixis CIB’s senior country manager for Greater China. “The deal also highlights the fact that there continues to be healthy levels of liquidity available to strategic private enterprises in China with good credit profiles.”
Nicholas Low, the bank’s head of healthcare industry for Asia-Pacific, adds: “China and the wider Asia-Pacific healthcare industry is at an inflection point, driven by a confluence of supportive demographics, evolving healthcare policies, improved resource allocation and, importantly, innovation fuelling sector growth in the coming years.”